Inflammaskin ® enables evaluation of targeted immunomodulatory therapies in a psoriasis-like human skin model (ESDR 2026) - Oct 5, 2026 - Abstract #110; "We then evaluated inflammation resolution following the administration of betamethasone, and secukinumab to assess the relevance of this model for the evaluation of immunomodulatory therapies...These results demonstrate that InflammaSkin ® recapitulates key features of T cell-mediated psoriasis-like inflammation. Its translational relevance supports the evaluation of immunomodulatory effects and positions as a valuable solution for assessing inflammation resolution following administration of targeted therapeutics."
Immunomodulating • Dermatology • Immunology • Inflammation • Psoriasis • CCL4 • CSF2 • CXCL8 • GZMB • IFNG • IL10 • IL15 • IL16 • IL17A • IL22 • IL5 • IL7 • TNFA
|
|
Nicolas Giang 1; Jeremy Argenty 1; Alexandra Ochando 1; Nicolas Gaudenzio 1,2; Emeline Pagès 1
|